Form 4: Corcept Therapeutics CEO Trades Shares

Corcept Therapeutics CEO Joseph K. Belanoff reported transactions involving company stock, including acquisitions and a sale executed under a Rule 10b5-1 plan.

Summary

• Joseph K. Belanoff, CEO of Corcept Therapeutics, engaged in several stock transactions on May 29, 2026, and June 1, 2026.
• On May 29, 2026, 300,000 shares of common stock were acquired by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust, with Mr. Belanoff disclaiming beneficial ownership except for his pecuniary interest.
• Also on May 29, 2026, 150,000 shares were transferred without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, where Mr. Belanoff is the trustee.
• Concurrently, 150,000 shares were transferred without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust, where Mr. Belanoff's spouse is the trustee.
• On June 1, 2026, 12,837 shares were disposed of by Mr. Belanoff under a Rule 10b5-1 trading plan adopted on November 26, 2024, at a price of $69.74 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it details standard insider transactions and estate planning activities, with a sale executed under a pre-arranged plan, which is a common and expected practice.

Positives

• The establishment and execution of a Rule 10b5-1 trading plan indicates proactive and structured financial planning by management.
• The transfer of shares to trusts for estate planning purposes can be viewed as prudent financial management.

Negatives

• A sale of company stock by the CEO, even under a pre-arranged plan, can sometimes be perceived negatively by the market.
• The total number of shares disposed of in the reported transaction is 12,837.

Risks

• The Rule 10b5-1 trading plan, while providing an affirmative defense against insider trading allegations, still involves the disposition of company stock by a key executive.
• The market's perception of insider selling, regardless of the plan, could potentially impact share price.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding future financial performance. The primary forward-looking aspect relates to the ongoing execution of the Rule 10b5-1 trading plan.

Management Comments

• Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
• Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust.
• Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee.
• Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust.
• Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors, providing transparency on insider stock transactions. The use of a Rule 10b5-1 plan by Corcept Therapeutics' CEO is a common strategy to manage personal stock sales while adhering to insider trading regulations, especially in the biopharmaceutical sector where stock-based compensation is prevalent and stock price can be volatile.

Related Party Transactions

• Transfer of 150,000 shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which Joseph K. Belanoff is the trustee.
• Transfer of 150,000 shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of Joseph K. Belanoff is the trustee.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, even under a 10b5-1 plan, may be viewed with caution, though the plan itself is designed to mitigate insider trading concerns.
• Employees: The transactions do not directly impact employees but reflect the financial activities of senior leadership.
• Creditors: No direct impact on creditors is indicated by these stock transactions.

Next Steps

• Continued adherence to the Rule 10b5-1 trading plan for future stock dispositions, if applicable.
• Monitoring of future Form 4 filings for any additional insider transactions.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Trading, Stock Transaction, Rule 10b5-1, Joseph K. Belanoff, CEO, Beneficial Ownership, Securities Exchange Act